Funds · 13F holdings

MPM Bioimpact LLC

13F holdings for Q2 2026 · BOSTON, MA · filed August 14, 2026

MPM Bioimpact LLC reported $1.6B in 13F securities across 37 holdings for Q2 2026, in a Form 13F filed August 14, 2026. The largest positions were CGEM (10.8%), AKTS (9.5%), LQDA (6.7%). Reported value rose 26.6% from the quarter before. It opened 7 new positions, added to 7, trimmed 22 and sold out of 11.

13F value Q2 2026
$1.6B
Holdings
37
Change vs prior quarter
+26.6%
Rank by 13F value
#1,855

Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.

Top holdings

StockValueWeightSharesChange in sharesMove
CGEM Cullinan Therapeutics Inc.$177M10.8%9,731,341+27.2%Added
AKTS Aktis Oncology Inc.$156M9.5%4,835,8720%Unchanged
LQDA Liquidia Corporation$111M6.7%1,386,174-1.4%Trimmed
RVMD Revolution Medicines Inc.$92.2M5.6%492,483-2.8%Trimmed
CORT Corcept Therapeutics Incorporated$67.0M4.1%771,028-21.8%Trimmed
EWTX Edgewise Therapeutics Inc.$65.9M4.0%1,620,780-2.4%Trimmed
TVTX Travere Therapeutics Inc.$63.8M3.9%1,122,731-0.9%Trimmed
DBVT DBV Technologies S.A.$60.1M3.7%3,666,284-29.7%Trimmed
TRVI Trevi Therapeutics Inc.$57.3M3.5%3,073,577-6.8%Trimmed
ALMS Alumis Inc.$56.8M3.5%2,019,020-15.4%Trimmed
Uniqure NV$56.5M3.4%1,225,855-10.5%Trimmed
RARE Ultragenyx Pharmaceutical Inc.$47.4M2.9%1,418,215NewNew
RLAY Relay Therapeutics Inc.$45.2M2.8%2,415,672+2.4%Added
ABVX Abivax SA$44.8M2.7%336,347+213.6%Added
DYN Dyne Therapeutics Inc.$42.7M2.6%1,922,093+36.5%Added
DNTH Dianthus Therapeutics Inc.$40.9M2.5%420,002-0.9%Trimmed
BIOA BioAge Labs Inc.$40.9M2.5%1,667,661NewNew
Urogen Pharma LTD$34.3M2.1%933,415-1.1%Trimmed
MLTX MoonLake Immunotherapeutics$31.3M1.9%1,606,967-11.3%Trimmed
PVLA Palvella Therapeutics Inc.$31.2M1.9%204,027-1.2%Trimmed
TSHA Taysha Gene Therapies Inc.$30.6M1.9%4,500,000NewNew
SNDX Syndax Pharmaceuticals Inc.$29.2M1.8%1,333,523-0.5%Trimmed
GLUE Monte Rosa Therapeutics Inc.$28.1M1.7%1,161,081-1.3%Trimmed
Zura Bio LTD$26.4M1.6%4,472,843NewNew
NTRA Natera Inc.$25.1M1.5%92,638-0.5%Trimmed

Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $1.6B in share positions; options and bonds count in the 13F value but not here.

The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 7 new, 7 added, 22 trimmed, 11 sold out.

Sector mix

13F value by quarter

Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Q2 '26
Reported 13F value: Q1 2024 $622M, Q2 2024 $644M, Q3 2024 $667M, Q4 2024 $704M, Q1 2025 $582M, Q2 2025 $577M, Q3 2025 $611M, Q4 2025 $874M, Q1 2026 $1.3B, Q2 2026 $1.6B.

More holdings

StockValueWeightSharesChange in sharesMove
STOK Stoke Therapeutics Inc.$23.7M1.4%723,314-5.7%Trimmed
ANL Adlai Nortye Group Ltd.$22.3M1.4%1,936,291NewNew
BLTE Belite Bio Inc$21.1M1.3%137,208+55.8%Added
Forte Biosciences Inc$21.0M1.3%987,448-1.3%Trimmed
ORIC Oric Pharmaceuticals Inc.$20.4M1.2%1,882,162+4.3%Added
TARS Tarsus Pharmaceuticals Inc.$20.3M1.2%322,007-2.3%Trimmed
ANNX Annexon Inc.$20.2M1.2%3,544,354NewNew
DRUG Bright Minds Biosciences Inc.$14.2M0.9%202,114-4.7%Trimmed
TRDA Entrada Therapeutics Inc.$9.2M0.6%1,253,053NewNew
ACRS Aclaris Therapeutics Inc.$5.5M0.3%1,042,467+166.0%Added
CNTX Context Therapeutics Inc.$720K0.0%1,299,046-87.8%Trimmed
HOWL Werewolf Therapeutics Inc.$29K0.0%80,142-93.4%Trimmed

Schedule 13D and 13G filings by MPM Bioimpact LLC

Stakes above 5% of a company, filed within days rather than once a quarter.

Questions about MPM Bioimpact LLC

What does MPM Bioimpact LLC own?
In its Form 13F for Q2 2026, MPM Bioimpact LLC reported 37 holdings worth $1.6B. The five largest were CGEM, AKTS, LQDA, RVMD, CORT.
What did MPM Bioimpact LLC buy and sell in Q2 2026?
MPM Bioimpact LLC opened 7 new positions, added to 7, trimmed 22 and sold out of 11 compared with the quarter before.
When did MPM Bioimpact LLC file its latest 13F?
Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 14, 2026.

From Form 13F filed by MPM Bioimpact LLC (SEC CIK 0001687078) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds